BCL-XL, a member of the pro-survival BCL-2 protein family, is frequently upregulated in tumors, disrupting the apoptotic balance and promoting tumorigenesis.302 While inhibitors targeting these proteins are used in cancer therapy, their clinical utility is limited by significant toxicity due to BCL-XL overexpression in platelets. Here, BCL2L1 is linked to cancer.